VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism (VERITAS)
Primary Purpose
Deep Vein Thrombosis, Pulmonary Embolus
Status
Withdrawn
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Veniti Inferior Vena Cava Filter
Sponsored by
About this trial
This is an interventional prevention trial for Deep Vein Thrombosis focused on measuring Inferior Vena Cava Filter, Vena Cava Filters
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 years
- Investigator judges caval filtration clinically indicated for prevention of pulmonary embolism in patient with venous thromboembolic disease or at high risk for venous thromboembolic disease. Patient must meet at least one of the following:
- Anticoagulant therapy is contraindicated, has failed, cannot be achieved or maintained, must be interrupted, resulted in complication, or places the patient at high risk of complication and the patient has:
- Pulmonary embolus
- Iliocaval deep vein thrombosis (DVT)
- Severe trauma with high risk of venous thromboembolism including closed head injury, spinal cord injury, or multiple long bone or pelvic fractures
- Surgery planned with high risk of venous thromboembolism including procedures such as bariatric, orthopedic, or pelvic surgery
- Past history of thromboembolic disease undergoing surgery
Therapeutic anticoagulation can be achieved, but the patient has:
- Venous thromboembolism such as pulmonary embolism or DVT with limited cardiopulmonary reserve
- Massive pulmonary embolism already treated with thrombectomy or any thrombolytic therapy
- Chronic pulmonary embolism already treated with thrombectomy
- Large, free floating proximal, e.g., iliofemoral or iliocaval, DVT
- Iliocaval DVT with planned catheter thrombectomy or thrombolysis treatment OR
- Medical condition with high risk of venous thromboembolism
Exclusion Criteria:
- Condition that inhibits radiographic visualization of the IVC
- Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC including occlusion of the SVC or jugular veins
- Known IVC transverse diameter at target implant site > 28 mm
- Known obstructing abdominal mass or anatomy that is not suitable for infra-renal placement of IVC filter
- Known duplication of IVC or left-sided IVC
- Severe kyphosis or scoliosis
- Known IVC thrombosis extending to renal veins, or renal or gonadal vein thrombosis
- Risk for septic pulmonary embolism
- Confirmed bacteremia
- Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min, or dialysis dependent.
- Contrast agent allergy that cannot be adequately pre-medicated
- Known hypersensitivity to Nitinol (nickel-titanium), platinum, Polyether ether ketone (PEEK), UV Cure Adhesive or Cyanoacrylate Adhesive
- Uncontrolled or active coagulopathy or known uncorrectable bleeding diathesis
- Life expectance < 6 months
- Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study. (If a female of child bearing potential wishes to participate, she must have negative pregnancy test within 48 hours of the implantation and any retrieval procedures.)
- Has filter in place or underwent filter retrieval in previous 60 days
- Simultaneously participating in another therapeutic drug or device clinical trial or has participated in such trial in the 30 days prior to enrollment
- Investigator considers patient to be a poor candidate for the study or that including the patient may compromise the study, e.g., suspect patient may not comply with follow up procedures, concomitant conditions
- Patient does not wish to consent to study or comply with study procedures, including possible 2 year follow up
Sites / Locations
- Alfred Hospital
- Auckland City Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Veniti Inferior Vena Cava Filter
Arm Description
Outcomes
Primary Outcome Measures
Clinical Success
The endpoint is clinical success (versus failure) at 6 months after implant or 1 month post retrieval, whichever occurs first, based on the definition provided by the SIR guidelines, as the absence of:
Procedure failure (assessed at the end of the implant procedure)
Subsequent pulmonary embolus
IVC occlusion
Filter embolization
Secondary Outcome Measures
Secondary Endpoint
Estimating the rate of:
Retrieval success
Device and procedure related adverse events
filter performance rate
Assessing filter performance rate:
Filter migration
Filter fracture
Filter Tilt
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01787773
Brief Title
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
Acronym
VERITAS
Official Title
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Withdrawn
Why Stopped
IDE was withdrawn. Veniti no longer owns the rights to this device.
Study Start Date
March 2013 (Anticipated)
Primary Completion Date
April 2015 (Anticipated)
Study Completion Date
April 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Veniti
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a prospective, multicenter single arm, nonrandomized study that will include 150 patients at a maximum of 20 investigational sites. It is estimated that it may take 13 months to complete enrollment. Follow-up will continue through 24 months post-implant or one month post-retrieval, whichever occurs first. It is required that filters be retrieved from at least 50 patients and the filter is permanent in at least 50 patients.
Detailed Description
Verify the effectiveness and safety of the Veniti IVC Filter in accordance with the clinical guidelines published by the Society for Interventional Radiology (SIR) .
The endpoint is clinical success (versus failure) at 6 months after implant or 1 month post retrieval, whichever occurs first, based on the definition provided by the SIR guidelines, as the absence of:
Procedure failure (assessed at the end of the implant procedure)
Subsequent pulmonary embolus
IVC occlusion
Filter embolization
Secondary assessments include:
Estimating the rate of:
Retrieval success
Device and procedure related adverse events
Assessing filter performance rate:
c1.Filter migration c2.Filter fracture c3.Filter Tilt
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Deep Vein Thrombosis, Pulmonary Embolus
Keywords
Inferior Vena Cava Filter, Vena Cava Filters
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Veniti Inferior Vena Cava Filter
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Veniti Inferior Vena Cava Filter
Primary Outcome Measure Information:
Title
Clinical Success
Description
The endpoint is clinical success (versus failure) at 6 months after implant or 1 month post retrieval, whichever occurs first, based on the definition provided by the SIR guidelines, as the absence of:
Procedure failure (assessed at the end of the implant procedure)
Subsequent pulmonary embolus
IVC occlusion
Filter embolization
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Secondary Endpoint
Description
Estimating the rate of:
Retrieval success
Device and procedure related adverse events
Time Frame
24 months
Title
filter performance rate
Description
Assessing filter performance rate:
Filter migration
Filter fracture
Filter Tilt
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥ 18 years
Investigator judges caval filtration clinically indicated for prevention of pulmonary embolism in patient with venous thromboembolic disease or at high risk for venous thromboembolic disease. Patient must meet at least one of the following:
Anticoagulant therapy is contraindicated, has failed, cannot be achieved or maintained, must be interrupted, resulted in complication, or places the patient at high risk of complication and the patient has:
Pulmonary embolus
Iliocaval deep vein thrombosis (DVT)
Severe trauma with high risk of venous thromboembolism including closed head injury, spinal cord injury, or multiple long bone or pelvic fractures
Surgery planned with high risk of venous thromboembolism including procedures such as bariatric, orthopedic, or pelvic surgery
Past history of thromboembolic disease undergoing surgery
Therapeutic anticoagulation can be achieved, but the patient has:
Venous thromboembolism such as pulmonary embolism or DVT with limited cardiopulmonary reserve
Massive pulmonary embolism already treated with thrombectomy or any thrombolytic therapy
Chronic pulmonary embolism already treated with thrombectomy
Large, free floating proximal, e.g., iliofemoral or iliocaval, DVT
Iliocaval DVT with planned catheter thrombectomy or thrombolysis treatment OR
Medical condition with high risk of venous thromboembolism
Exclusion Criteria:
Condition that inhibits radiographic visualization of the IVC
Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC including occlusion of the SVC or jugular veins
Known IVC transverse diameter at target implant site > 28 mm
Known obstructing abdominal mass or anatomy that is not suitable for infra-renal placement of IVC filter
Known duplication of IVC or left-sided IVC
Severe kyphosis or scoliosis
Known IVC thrombosis extending to renal veins, or renal or gonadal vein thrombosis
Risk for septic pulmonary embolism
Confirmed bacteremia
Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min, or dialysis dependent.
Contrast agent allergy that cannot be adequately pre-medicated
Known hypersensitivity to Nitinol (nickel-titanium), platinum, Polyether ether ketone (PEEK), UV Cure Adhesive or Cyanoacrylate Adhesive
Uncontrolled or active coagulopathy or known uncorrectable bleeding diathesis
Life expectance < 6 months
Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study. (If a female of child bearing potential wishes to participate, she must have negative pregnancy test within 48 hours of the implantation and any retrieval procedures.)
Has filter in place or underwent filter retrieval in previous 60 days
Simultaneously participating in another therapeutic drug or device clinical trial or has participated in such trial in the 30 days prior to enrollment
Investigator considers patient to be a poor candidate for the study or that including the patient may compromise the study, e.g., suspect patient may not comply with follow up procedures, concomitant conditions
Patient does not wish to consent to study or comply with study procedures, including possible 2 year follow up
Facility Information:
Facility Name
Alfred Hospital
City
Melbourne
ZIP/Postal Code
3004
Country
Australia
Facility Name
Auckland City Hospital
City
Grafton
ZIP/Postal Code
1142
Country
New Zealand
12. IPD Sharing Statement
Learn more about this trial
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
We'll reach out to this number within 24 hrs